WideScreen™ Human Cancer Panel 1

WideScreen™ EpiTag™ Assays Overview Technology ERK Data Available Assays WideScreen™ RTK Assays RTK Assays RTK Data Available Assays WideScreen™ Biomarker Assays Human Cancer Panel 1 (Tumor Markers) Human Cancer Panel 2 (Growth Factors) Human CVD Panel 1 (Apolipoprotein) Human CVD Panel 2 (Inflammation) Human CVD Panel 3 Human CVD Panel 4 Human CVD Panel 5 (Acute Phase) Human CVD Panel 6

The WideScreen™ Human Cancer Panel 1 (Tumor Markers) is a pre-mixed multiplex bead kit of quantitative antibody-based assays for simultaneous detection of six tumor-associated human proteins found in biological fluids: AFP (a-fetoprotein), CA 125, CA15-3, CA 19-9, CEA (carcinoembryonic antigen), and prolactin. The kit includes all the reagents, controls, and buffers needed to analyze the above proteins in serum, plasma, and tissue culture supernatants using the Luminex® xMAP® System.

Resources:
Sample Certificate of Analysis

Technical Bulletin:
Pricing and ordering information: click here

 

Product Cat. No. WideScreen™ Human Cancer Panel 1  NEW! 71984 WideScreen™ Human Cancer Panel 2  NEW! 71995

Tumor marker levels in human sera
The WideScreen Human Cancer Panel 1 multiplex was used to quantify biomarker levels in randomly selected serum samples from normal and disease state patients: Normal (N,, n=4); Breast cancer (BR,, n=2); Ovarian cancer (OV,, n=3); Colorectal cancer (CR,, n=4); Gastrointestinal cancer (GI,, n=2). Sera from normal individuals have tumor marker concentrations within the normal range, whereas high concentrations of tumor-associated antigens are found in some disease state patients.

View larger version
[In this window]
[In a new window]

Performance Characteristics

Species	Human, other species not tested
Sample Size	6 µl
Sample Types	Serum, plasma, tissue culture supernatants
Linearity .% recovery across dilutions . .	Dilution 1:10 1:20 1:40 .	Range 91%-111% 92%-103% 93%-111%
Intra-assay CV	3%-15%
Inter-assay CV	7%-24%
Cross-reactivity	Negligible
Matrix Interference Analyte recovery in the presence of:	Hemoglobin (5mg/ml) 72% to 100%  Bilirubin (0.2 mg/ml) 81% to 92% Triglycerides (5mg/ml) 101% to 126%

Association of Marker with Cancer Type

Marker	Breast	Colorectal	Liver	Lung	Ovarian	Pancreatic
AFP	•		•		•
CA 125					•
CA 15-3	•
CA 19-9		•				•
CEA	•	•		•
Prolactin	•	•			•

 

Analyte	Standard Range	Assay LDD	Average Recovery from Serum	Average Recovery from EDTA Plasma	Normal Range*
AFP	0.15-333 ng/ml	0.15 ng/ml	92%	101%	<20 ng/ml
CA 125	0.55-1200 U/ml	0.30 U/ml	144%	131%	<35 U/ml
CA 15-3	0.18-392 U/ml	0.18 U/ml	96%	108%	<25 U/ml
CA 19-9	0.15-320 U/ml	0.15 U/ml	87%	98%	<37 U/ml
CEA	0.017-37 ng/ml	0.017 ng/ml	76%	84%	<5 ng/ml
Prolactin	0.017-38 ng/ml	0.017 ng/ml	72%	74%	<29 ng/ml**

^*Normal range data from American Cancer Society website, www.cancer.org and other sources.
^**Pregnant women: 10-209 ng/ml

The WideScreen Human Cancer Panel 1 uses the same reagents and technologies
developed by Rules Based Medicine for the use in their industry-leading biomarker
testing service along with the expertise of Novagen in commercializing and supporting
high value products. Accordingly, the kits are supplied with the highest quality and
relevant validation data, ensuring that each assay kit meets the stringent quality and
performance required in today’s demanding research environment.